13 assets in Squamous Cell Carcinoma Of Rectum

Therapeutic assets addressing Squamous Cell Carcinoma Of Rectum, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Capecitabine Squamous Cell Carcinoma Of Rectum	National Cancer Institute (NCI)	P2	CCC (53)
e7 tcr-t cells Squamous Cell Carcinoma Of Rectum	Christian Hinrichs	P2	CCC (53)
Fludeoxyglucose Squamous Cell Carcinoma Of Rectum	National Cancer Institute (NCI)	P2	CCC (53)
Fluorouracilum Squamous Cell Carcinoma Of Rectum	National Cancer Institute (NCI)	P2	CCC (53)
Muamycin Squamous Cell Carcinoma Of Rectum	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Squamous Cell Carcinoma Of Rectum	National Cancer Institute (NCI)	P2	CCC (53)
Tsc-200-A0201 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-201-B0702 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-202-A0201 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-203-A0201 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-A0101 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-A0201 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-C0702 Squamous Cell Carcinoma Of Rectum	TScan Therapeutics, Inc.	P1	CC (43)